Investor Presentaiton

Strong track record Unique model Large moat Siginficant opportunity Compounding growth Long duration portfolio consistently replenished Duration of portfolio (At IPO) (by NPV) Duration of royalties acquired 2020-2022 YTD (Today) (by NPV) Duration of portfolio (Today) (by NPV) Beyond 2030 + ~70% Beyond 2030 ~90% ~13 year weighted average royalty portfolio duration ROYALTY PHARMA IPO: initial public offering; NPV: net present value Beyond 2030 ~80% 18

View entire presentation